Potential drug-drug interactions in hospitalized patients with chronic heart failure and chronic obstructive pulmonary disease

Archives of Medical Science

Volumn 10, Issue 5, 2014, Pages 920-932

  Roblek, Tina ^a   Trobec, Katja ^b   Mrhar, Ales ^a   Lainscak, Mitja ^b,c  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b University Clinic of Pulmonary and Allergic Diseases Golnik   (Slovenia)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Chronic heart failure; Chronic obstructive pulmonary disease; Potential drug drug interactions

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIPERIDEN; CALCIUM CHANNEL BLOCKING AGENT; CLOZAPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETIRACETAM; FENTANYL; GLYCERYL TRINITRATE; HALOPERIDOL; IPRATROPIUM BROMIDE; LOOP DIURETIC AGENT; MIANSERIN; MOXONIDINE; PIRACETAM; RISPERIDONE; SULPIRIDE; THIETHYLPERAZINE; TIANEPTINE; TIOTROPIUM BROMIDE; TRAMADOL; UNINDEXED DRUG; WARFARIN; ZOLPIDEM; ZUCLOPENTHIXOL;

AGED; ANTICHOLINERGIC EFFECT; ARTICLE; CENTRAL NERVOUS SYSTEM DEPRESSION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DRUG INTERACTION; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; POLYPHARMACY; PRESCRIPTION; TARDIVE DYSKINESIA;

EID: 84908416368     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2014.46212     Document Type: Article

References (39)

1. Moura C, Acurcio F, Belo N. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharmaceut Sci 2009; 12: 266-72.
2. Piromohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15-9.
3. Juurlink DM, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289: 1652-8.
4. Björkman KI, Fastborn J, Schmidt IK, et al. Drug-drug interactions in elderly. Ann Pharmacother 2002; 36: 1675-81.
5. Gallagher P, Barry P, O'Mahony D. Inappropriate prescribing in the elderly. J Clin Pharm Ther 2007; 32: 113-21.
6. Radošević N, Gantumur M, Vlahović-Palčevski V. Potentially inappropriate prescribing to hospitalised patients. Pharmacoepidemiol Drug Saf 2008; 17: 733-7.
7. Vonbach P, Dubied A, Krähenbühl S, et al. Prevalence of drug-drug interactions at a hospital entry and during hospital stay of patients in internal medicine. Eur J Int Med 2008; 19: 413-20.
8. Straubhaar B, Krähenbühl S, Schlienger RG. The prevalence of potential drug-drug interactions in patients with heart failure at hospital discharge. Drug Saf 2006; 29: 79-90.
9. Alderman CP. Patient-oriented strategies for the prevention of drug interactions. Drug Saf 2000; 22: 103-9.
10. Goldberg RM, Mabee J, Chan L, et al. Drug-drug and drug-disease interactions in ED: analysis of high-risk population. Am J Emerg Med 1996; 14: 447-50.
11. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary. Am J Respir Crit Care Med 2007; 176: 532-55.
12. McMurray JJV, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur J Heart Fail 2012; 14: 803-69.
13. Düngen HD, Apostolović S, Inkrot S, et al. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail 2011; 13: 670-80.
14. Egger SS, Drewe J, Schlienger RG. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 2003; 58: 773-8.
15. Vonbach P, Dubied A, Krähenbühl S, et al. Evaluation of frequently used drug interaction screening programs. Pharm World Sci 2008; 30: 367-74.
16. Smithburger PL, Kane-Gill SL, Seybert AL. Drug-drug interactions in cardiac and cardiothoracic intensive care units. Drug Saf 2010; 33: 879-88.
17. Bacic-Vrca V, Marusic S, Erdeljec V, et al. The incidence of potential drug-drug interactions in elderly patients with arterial hypertension. Pharm World Sci 2010; 32: 815-21.
18. Smithburger PL, Kane-Gill SL, Benedict NJ, et al. Grading the severity of drug-drug interactions in the intensive care unit: a comparison between clinician assessment and proprietary database severity rankings. Ann Pharmacother 2010; 44: 1718-24.
19. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
20. Lainščak M, Cleland JGF, Lenzen MJ, et al. International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure Survey. Eur J Heart Fail 2007; 9: 292-9.
21. Sarc I, Jeric T, Ziherl K, et al. Adherence to treatment guidelines and long-term survival in hospitalized patients with chronic obstructive pulmonary disease. J Eval Clin Pract 2011; 17: 737-43.
22. Lainscak M, Majc Hodoscek M, Dungen HD, et al. The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure. Wien Klin Wochenschr 2009; 121: 309-13.
23. Fotker N, Mozina M, Brvar M. Potential drug-drug interactions and admissions due to drug-drug interactions in patients treated in medical departments. Wien Klin Wochenschr 2010; 122: 81-8.
24. Kotlyar E, Keogh AM, Macdonald PS, et al. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease and asthma. J Heart Lung Transpl 2002; 21: 1290-5.
25. Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease. Am J Coll Cardiol 2010; 55: 1780-7.
26. Lainscak M, Podbregar M, Kovacic D, et al. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. Respir Med 2011; 105 (Suppl. 1): S44-9.
27. Antczak A, Ciebiata M, Pietras T, et al. Exhaled eicosanoids and biomarkers of oxidative stress in exacerbation of chronic obstructive pulmonary disease. Arch Med Sci 2012; 8: 277-85.
28. Wozniak K, Sleszycka J, Safinowska A, et al. Systemic inflammation in peripheral arterial disease with or without coexistent chronic obstructive pulmonary disease: analysis of selected markers. Arch Med Sci 2012; 8: 477-83.
29. Kovačič D, Marinšek M, Gobec L, et al. Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. Clin Res Cardiol 2008; 97: 24-31.
30. Lainscak M, Keber I, Anker SD. Body composition changes in patients with systolic heart failure treated with beta blockers: a pilot study. Int J Cardiol 2006; 106: 319-22.
31. Wojticzak-Soska K, Pietrucha T, Sakowicz A, et al. Soluble ST2 protein in chronic heart failure is independent of traditional factors. Arch Med Sci 2013; 9: 21-6.
32. Spina E, de Leon J. Metabolic drug interaction with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007; 100: 4-22.
33. Schlipak MG. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Int Med 2003; 138: 917-24.
34. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. NEJM 2004; 351: 543-51.
35. Lainscak M, Moullet C, Schön N, et al. Treatment of chronic heart failure with carvedilol in daily practice: the SATELLITE survey experience. Int J Cardiol 2007; 122: 149-55.
36. Farkas J, von Haehling S, Kalantar-Zadeh K, et al. Cachexia as a major public health problem: frequent, costly, and deadly. J Cachexia Sarcopenia Muscle 2013; 4: 173-8.
37. Lainscak M, Blue L, Clark AC, et al. Self-management of heart failure: practical recommendations from patient care committee of the heart failure association of the European Society of Cardiology. Eur J Heart Fail 2011; 13: 115-26.
38. Gonseth J, Guallar-Castillon P, Banegas JR, et al. The effectiveness of disease management programs in reducing re-admission in older patients with heart failure: a systematic review and meta-analysis of published reports. Eur Heart J 2004; 25: 1570-95.
39. Lainščak M, Keber I. Patients' knowledge and beta blocker treatment improve prognosis of patients from a heart failure clinic. Eur J Heart Fail 2006; 8: 187-90.